Treatment costs related to bipolar disorder and comorbid conditions among medicaid patients with bipolar disorder

Psychiatric Services

Volumn 58, Issue 8, 2007, Pages 1073-1078

  Guo, Jeff J ^a   Keck, Paul E ^b   Li, Hong ^d   Patel, Nick C ^b,c  

^a UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LITHIUM; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BILLING AND CLAIMS; BIPOLAR DISORDER; CHILD; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DRUG ABUSE; DRUG USE; ECONOMIC ASPECT; FEMALE; HEALTH INSURANCE; HOSPITAL COST; HOSPITAL SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MONOTHERAPY; OUTPATIENT CARE; PRESCRIPTION; REGRESSION ANALYSIS; RISK FACTOR;

EID: 34548059186     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2007.58.8.1073     Document Type: Article

References (41)

1. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC, 1994
2. Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry 62:617-627, 2005
3. Hirschfeld RM, Calabrese JR, Weissman MM, et al: Screening for bipolar disorder in the community. Journal of Clinical Psychiatry 64:53-59, 2003
4. Akiskal HS, Bourgeois ML, Angst J, et al: Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. Journal of Affective Disorders 59(suppl 1):S5-S30, 2000
5. Koenigsberg HW, Kaplan RD, Gilmore MM, et al: The relationship between syndrome and personality disorder in DSM-III: experience with 2,462 patients. American Journal of Psychiatry 142:207-221,1985
6. Brady KT, Lydiard RB: Bipolar affective disorder and substance abuse. Journal of Clinical Psychopharmacology 12(suppl 1):17S-22S, 1992
7. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorder in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 51:8-19, 1994
8. Weissman MM, Bruce LM, Leaf PJ, et al: Affective disorders, in Psychiatric Disorders in America: The Epidemiological Catchment Area Study. Edited by Robins IN, Regier DA. New York, Free Press, 1991
9. Winokur G, Coryell W, Akiskal HS, et al: Alcoholism in manic depressive (bipolar) illness, familial illness, course of illness, and the primary-secondary distinction. American Journal of Psychiatry 152:365-372, 1995
10. Feinman J, Dunner D: The effect of alcoholism and substance abuse on the course of bipolar affective disorder. Journal of Affective Disorders 37:43-49,1996
11. McElroy SL, Altshuler LL, Suppes T, et al: Axis I psychiatric comorbidity and its relationship with the historical illness variables in 288 patients with bipolar disorder. American Journal of Psychiatry 158:420-426, 2001
12. Escamilla MA, Batki S, Reus VI, et al: Comorbidity of bipolar disorder and substance abuse in Costa Rica: pedigree- and population-based studies. Journal of Affective Disorders 71:71-83, 2002
13. Goodwin RD, Hoven CW: Bipolar-panic comorbidity in the general population: prevalence and associated morbidity. Journal of Affective Disorders 70:27-33, 2002
14. George EL, Miklowitz DJ, Richards JA, et al: The comorbidity of bipolar disorder and axis II personality disorders: prevalence and clinical correlates. Bipolar Disorder 5:115-122, 2003
15. Keck PE, McElroy SL, Strackowski SM, et al: 12-month outcome of patients with bipolar disorder following hospitalization for a major or mixed episode. American Journal of Psychiatry 155:646-652, 1998
16. Keck PE, McElroy SL: Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. Journal of Clinical Psychiatry 64:1426-1435, 2003
17. Wozniak J, Biederman J, Monuteaux MC, et al: Parsing the comorbidity between bipolar disorder and anxiety disorders: a familial risk analysis. Journal of Child and Adolescent Psychopharmacology 12:101-111, 2002
18. Wyatt RJ, Henter I: An economic evaluation of manic-depressive illness, 1991. Social Psychiatry and Psychiatric Epidemiology 30:213-219, 1995
19. Begley CE, Annegers JF, Swann AC, et al: The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19:483-495, 2001
20. Gupta DR, Guest JF: Annual cost of bipolar disorder to UK society. Journal of Psychiatry 180:227-233, 2002
21. Stender M, Bryant-Comstock L, Phillips S: Medical resource use among patients treated for bipolar disorder: a retrospective, cross-sectional, descriptive analysis. Clinical Therapeutics 24:1668-1676, 2002
22. Simon GE, Unützer J: Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatric Services 50:1303-1308, 1999
23. Koyanagi C, Forguer S, Alfano E: Medicaid policies to contain psychiatric drug costs. Health Affairs 24:536-544, 2005
24. Heisler M, DeMonner SM, Billi JE, et al: Medicaid managed care: are academic medical centers penalized by attracting patients with high-cost conditions? American Journal of Managed Care 9:19-29, 2003
25. Li J, McCombs JS, Stimmel GL: Cost of treating bipolar disorder in the California Medicaid (Medi-Cal) program. Journal of Affective Disorders 71:131-139, 2002
26. Keck PE, McElroy SC: Treatment of bipolar disorder, in American Psychiatric Association Textbook of Psychopharmacology, 3rd edition. Edited by Schatzberg AF, Nemeroff CB. Arlington, Va, American Psychiatric Publishing, 2004
27. Keck PE Jr, Marcus R, Tourkodimitris S, et al: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160:1651-1658, 2003
28. Blanco C, Laje G, Olfson M, et al: Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 159:1005-1010, 2002
29. Guo JJ, Gibson JT, Gropper DM, et al: Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. American Journal of Managed Care 4:1433-1446, 1998
30. Guo JJ, Keck PE, Corey-Lisle PK, et al: Diabetes mellitus associated with antipsychotic use among patients with bipolar disorders: a retrospective, population-based case-control study. Journal of Clinical Psychiatry 67:1055-1061, 2006
31. Strom BL, Carson JL, Halpern AC, et al: A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Archives of Dermatology 127:831-838, 1991
32. Consumer Price Index for all urban consumers 1998, 1999, 2000, 2001, 2002. Washington DC, US Department of Labor, Bureau of Labor Statistics. Available at www.bls.gov
33. Bureau of Labor Statistics. Medical care inflation continues to rise. Washington DC, US Department of Labor, Bureau of Labor Statistics, May 29, 2001. Available at www.bls.gov/opub/ted/2001
34. Hilty DM, Brady KT, Hales RE: A review of bipolar disorder among adults. Psychiatric Services 50:201-213, 1999
35. Austin PC, Ghali WA, Tu JV: A comparison of several regression models for analyzing cost of CABG surgery. Statistics in Medicine 22:2799-2815, 2003
36. Regier D, Narrow WE, Rae DS, et al: The de facto US mental and addictive disorders services: Epidemiologic Catchment Area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry 50:85-94, 1993
37. Keck PE Jr, McElroy SL: Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opinion on Investigational Drugs 12:655-662, 2003
38. Hirschfeld RM, Keck PE Jr, Kramer M, et al: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. American Journal of Psychiatry 161:1057-1065, 2004
39. Moller HJ, Nasrallah HA: Treatment of bipolar disorder. Journal of Clinical Psychiatry 64(suppl 6):9-17, 2003
40. Mamo D, Kapur S, Shammi CM, et al: A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. American Journal of Psychiatry 161:818-825, 2004
41. Papakostas GI, Petersen TJ, Nierenberg AA, et al: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Journal of Clinical Psychiatry 65(2):217-221, 2004